• Markets
    • icon
  • Companies
GTG · ASX

Genetic Technologies Limited (ASX:GTG)

AU$0.003

 0.0 (0.0%)
ASX:Live
04/12/2023 03:56:25 PM
Near Support (Realtime) Near Resistance HALO Ords GROWTH AUS Big Candle (Realtime) +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

GTG Overview

GTG Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About GTG

Website

Genetic Technologies Limited

Telephone

61.3.8412.7000

Address

60-66 Hanover Street Fitzroy, Victoria (VIC) 3065

Description

Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA, AffinityDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment focuses on AffinityDNA branded test sales and expenses.The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

GTG Price Chart

Key Stats

Market Cap

AU$28.85M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.01

Trade Value (12mth)

AU$5,380.00

1 week

20%

1 month

50%

YTD

0%

1 year

0%

All time high

0.812

Key Fundamentals

EPS 3 yr Growth

-20.000%

EBITDA Margin

-127.70%

Operating Cashflow

-$10m

Free Cash Flow Return

-67.60%

ROIC

-83.30%

Interest Coverage

-375.70

Quick Ratio

3.10

Other Data

Shares on Issue (Fully Dilluted)

9234m

HALO Sector

Healthcare

Next Company Report Date

29-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

GTG Announcements

Latest Announcements

Date Announcements

31 December 08

2008 US Annual Report on Form 20-F

×

2008 US Annual Report on Form 20-F

31 August 23

2023 Annual Report and Appendix 4E

×

2023 Annual Report and Appendix 4E

31 August 23

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

31 August 23

Annual Results Momentum Building on our Commercial Plans

×

Annual Results Momentum Building on our Commercial Plans

31 August 21

Annual Report to Shareholders and Appendix 4E

×

Annual Report to Shareholders and Appendix 4E

30 October 23

Appendix 4C and Quarterly Activities Report - September 2023

×

Appendix 4C and Quarterly Activities Report - September 2023

30 October 20

Investor Presentation

×

Investor Presentation

30 October 18

Notice of 2018 Annual General Meeting/Proxy Form

×

Notice of 2018 Annual General Meeting/Proxy Form

30 October 14

US Annual Report on Form 20-F

×

US Annual Report on Form 20-F

30 June 22

GeneType Risk Assessment Test Onboarding in 16 clinics

×

GeneType Risk Assessment Test Onboarding in 16 clinics

30 January 23

Appendix 4C and Quarterly Business Update December 2022

×

Appendix 4C and Quarterly Business Update December 2022

30 August 22

Annual Report to Shareholders and Appendix 4E

×

Annual Report to Shareholders and Appendix 4E

30 August 22

GTG Building Momentum on Commercial Plans

×

GTG Building Momentum on Commercial Plans

30 August 22

Corporate Governance Statement and Appendix 4G

×

Corporate Governance Statement and Appendix 4G

29 September 23

Date of AGM and Closing Date for Director Nominations

×

Date of AGM and Closing Date for Director Nominations

29 September 22

GeneType Outperforms Traditional Risk Assessments

×

GeneType Outperforms Traditional Risk Assessments

29 November 18

2018 Annual General Meeting materials

×

2018 Annual General Meeting materials

29 November 18

Results from 2018 Annual General Meeting

×

Results from 2018 Annual General Meeting

29 November 13

2013 Annual General Meeting materials

×

2013 Annual General Meeting materials

29 December 09

F

×

F

28 September 23

GTG & Gold Coast Hospital Announce Precision Medicine Pilot

×

GTG & Gold Coast Hospital Announce Precision Medicine Pilot

28 November 22

AGM Presentation and Chairman's Address

×

AGM Presentation and Chairman's Address

28 November 22

Results of AGM

×

Results of AGM

28 November 12

ImmunAid Annual General Meeting

×

ImmunAid Annual General Meeting

28 July 23

Appendix 4C and Quarterly Activities Report - June 2023

×

Appendix 4C and Quarterly Activities Report - June 2023

28 July 22

Q4 FY22 Results Milestones and Growth

×

Q4 FY22 Results Milestones and Growth

28 July 21

Genetic Technologies Investor Presentation and Webinar

×

Genetic Technologies Investor Presentation and Webinar

GTG Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 46.7 0.0 -50.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.00 -0.00 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.6 4.0 -58.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -9.7 -20.6 -37.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 37.9 -48.8 -33.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 8,544 9,220 10,138 Lock Lock Lock
Basic m Lock Lock Lock Lock 8,544 9,220 10,138 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 7 9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 1,122.2 5,536.3 27.8 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 8 7 9 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -44.4 -272.1 -4.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -530.1 -35.0 -28.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 630 135 129 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -8 -9 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -14.0 -6.8 -27.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -6,760.3 -128.2 -127.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -9 -9 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.4 -7.6 -26.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -7,157.0 -136.7 -135.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -8 -10 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -7 -7 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -16.0 -0.8 -64.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5,870.9 -104.9 -135.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -6 -6 -10 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -3 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 14 0 6 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 -6 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -21.4 19.4 -67.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -58.6 -0.8 -1.1 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 21 12 8 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 23 21 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -21 -11 -7 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 4 4 Lock Lock Lock
Equity $m Lock Lock Lock Lock 22 16 11 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 22 17 11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 62.6 -22.0 -32.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -30.8 -34.3 -79.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -32.9 -43.4 -105.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -49.0 -47.8 -81.8 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -40.7 -37.2 -83.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -36.2 -29.3 -67.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -580.1 -572.3 -375.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.5 1.3 0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -96.1 -67.4 -65.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 15.8 3.9 3.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 15.8 3.8 3.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 94.0 79.7 74.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -449.0 -147.5 -287.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.1 3.9 4.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 9.0 38.6 30.8 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.6 1.2 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 223.7 17.0 9.6 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.6 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.6 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -6,698.7 -140.7 -155.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -35.2 -46.0 -91.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -30.8 -34.3 -79.1 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -32.9 -43.4 -105.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -32.9 -43.4 -105.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 40.4 9.5 11.8 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 2,821.3 93.9 91.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 2,861.8 103.3 103.1 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 151.8 27.4 32.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 2,709.9 76.0 70.3 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

GTG Shortsell

Frequently Asked Questions

The current share price of Genetic Technologies Limited (GTG:ASX) is AU$0.003.
The 52-week high share price for Genetic Technologies Limited (GTG:ASX) is AU$0.01.
The 52-week low share price for Genetic Technologies Limited (GTG:ASX)? is AU$0.00.
Genetic Technologies Limited (GTG:ASX) does not pay a dividend.
Genetic Technologies Limited (GTG:ASX) does not pay a dividend.
Genetic Technologies Limited (GTG:ASX) has a franking level of 0%.
Genetic Technologies Limited (GTG:ASX) is classified in the Healthcare.
The current P/E ratio for Genetic Technologies Limited (GTG:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.